---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-241942"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:32:35.717609+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaccinex presents pepinemab data at conferences; AD study completion expected Jun 2024, cancer ORR doubled

## Summary
- Pepinemab presentations at Keystone Symposia (Oct 1-5) and CTAD (Oct 24-27) featuring AD and cancer data.
- SIGNAL-AD phase 1/2a fully enrolled; last patient completes treatment by June 2024; key endpoints FDG-PET, CDR-SB, ADAS-Cog13.
- KEYNOTE-B84: In PD-L1 low HNSCC (CPS<20), ORR 21.1% and median PFS 5.79 months, ~2x historical checkpoint monotherapy.
- Combination with KEYTRUDA induces organized lymphoid structures correlated with disease control and PFS (p=0.0056).
- Vaccinex and Merck in preliminary stages of potential extension study adding chemotherapy to pepinemab+KEYTRUDA.

## SEC filing metadata
- accession: 0001193125-23-241942
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312523241942/0001193125-23-241942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312523241942/d481466d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-241942
- JSON: https://secwatch.observer/filing/0001193125-23-241942.json
- Plain text: https://secwatch.observer/filing/0001193125-23-241942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.